August 28, 2015

Alvogen on Wednesday announced that it will acquire a portfolio of four pharmaceutical products in the United States from Pfizer.

August 14, 2015
Pfizer on Friday announced that it would be selling four of its Canadian pharmaceutical products to alleviate concerns from Canada’s Competition Bureau and pave the way for its acquisition of Hospira. 
August 5, 2015

The approval of the acquisition— valued at $17 billion when it was announced in February — is based on Pfizer divesting certain products from its portfolio. 

July 17, 2015

Injectable and infusion drug company Hospira announced Thursday that the Food and Drug Administration had approved its bivalirudin injection, a generic of the Medicine Company’s Angiomax.

March 6, 2015

The Food and Drug Administration approved Zarxio, making it the first approved biosimilar product in the United States.

February 27, 2015

Remedies for conditions like hepatitis C, NASH (nonalcoholic steatohepatitis) and oncology will all help contribute to growth within the biotech sector, according to an analysis from Bloomberg Intelligence. 

February 10, 2015

The Generic Pharmaceutical Association on Monday announced the election of its 2015 executive committee and board of directors.

February 5, 2015

Pfizer has entered into a definitive merger agreement to acquire Hospira.


January 7, 2015

With tens and possibly hundreds of billions of dollars in potential savings still snagged in a regulatory limbo, federal lawmakers and health industry stakeholders strongly urged the Food and Drug Administration last month to knock down the final barriers to review and approval of biosimilar drugs for marketing in the United States.

October 7, 2014

Sandoz announced the launch of its dexmedetomidine hydrochloride injection, a generic version of Precedex from Hospira. 

September 11, 2014

Par Pharmaceutical Cos. earlier this week resumed shipping dexmedetomidine hydrochloride (HCl) injection, EQ 100 mcg base/mL, the generic form of Hospira's Precedex injection. 

August 19, 2014

The Food and Drug Administration has approved Mylan Institutional’s application for its dexmedetomidine hydrochloride injection, the company announced Tuesday. 

January 31, 2014

The imminent entry of several companies — including big pharma, small biotech and generic participants — into the global biosimilars space will propel the market toward exponential growth. The market is expected to soar from $1.2 billion in 2013 to $24 billion in 2019, reported Frost & Sullivan in research released earlier this week.

December 26, 2013

Earlier this year, the IMS Institute for Healthcare Informatics, the research wing of the healthcare industry analysis firm IMS Health, dropped a bombshell when it showed that U.S. spending on drugs fell in 2012, the first time that had happened in 55 years.

November 26, 2013

Generic drug maker Hospira will have its investor conference next week, the company said Tuesday.

November 18, 2013

The global market for biosimilars is expected to be worth nearly $2 billion before the end of the decade, according to a new study.

November 12, 2013

Hospira had sales of $1 billion in third quarter 2013, the generic drug maker said.

November 5, 2013

A recently released clinical trial has found that patients taking a biotech drug for arthritis and those taking a biosimilar version had similar responses to both treatments.

October 25, 2013

Three pharmacy groups are petitioning the World Health Organization to uphold common generic names for biosimilars and their branded reference products.

October 23, 2013

Drug maker Hospira is investing more than $200,000 at a plant in Rocky Mount, N.C., that will evaluate and test more than 450 products, the company said Wednesday.

October 22, 2013

A top executive of generic drug maker Hospira spoke in favor of giving biosimilar drugs the same generic names as the branded biologics they're based on.

October 17, 2013

As knock-off versions of biotech drugs get closer to reality in the United States, one issue that has emerged has centered on what to call them.

October 10, 2013

When it comes to laws and regulations, what happens in Europe stays in Europe generally, and doesn’t have much bearing on the United States. But a recent win in Europe for U.S. drug maker Hospira could have some implications for the United States as well.

September 19, 2013

A trade group for the generic pharmaceutical industry is hoping the Food and Drug Administration will allow biosimilars to share the same generic names as their branded biologic counterparts, saying that giving biosimilars their own generic names would not enhance safety.